Epileptic Encephalopathy clinical trials at UCSF

4 in progress, 2 open to eligible people

Epileptic encephalopathy is a serious condition that leads to frequent seizures and developmental delays. UCSF is conducting a study on CNKSR2 epilepsy aphasia syndrome to understand its impact. Another UCSF trial is testing a medication for SCN8A developmental and epileptic encephalopathy.

Showing trials for

  • NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

    open to eligible people ages 2-21

    The objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).

    San Francisco, California and other locations

  • CNKSR2 Natural History Study

    open to eligible people ages 6-21

    This prospective natural history study is being conducted to define the electroclinical, neurodevelopmental, and behavioral characteristics of CNKSR2 epilepsy aphasia syndrome (EAS) and intellectual disability (ID) in children aged 6 to 21 years old with CNKSR2 mutations. The data collected from this study will serve as an external control to eventual clinical trials examining precision medicine investigational therapeutics that aim to improve the seizure burden and neurodevelopmental outcomes in patients with CNKSR2 EAS/ID.

    San Francisco, California

  • Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE

    Sorry, accepting new patients by invitation only

    Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).

    San Francisco, California and other locations

  • LP352 in Subjects With Developmental and Epileptic Encephalopathy

    Sorry, in progress, not accepting new patients

    The objective of this study is to assess the long-term safety, tolerability, and efficacy of adjunctive therapy of LP352 in subjects with developmental and epileptic encephalopathies who completed participation in Study LP352-201.

    San Francisco, California and other locations

Last updated: